Zhong Weixia, Darmani Nissar A
Department of Basic Medical Sciences, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, United States.
Front Pharmacol. 2021 Sep 10;12:736842. doi: 10.3389/fphar.2021.736842. eCollection 2021.
Gq and Gβγ protein-dependent phospholipase C (PLC) activation is extensively involved in G protein-coupled receptor (GPCR)-mediated signaling pathways which are implicated in a wide range of physiological and pathological events. Stimulation of several GPCRs, such as substance P neurokinin 1-, dopamine D-, histamine H- and mu-opioid receptors, can lead to vomiting. The aim of this study was to investigate the role of PLC in vomiting through assessment of the emetic potential of a PLC activator (m-3M3FBS), and the antiemetic efficacy of a PLC inhibitor (U73122), in the least shrew model of vomiting. We find that a 50 mg/kg (i.p.) dose of m-3M3FBS induces vomiting in ∼90% of tested least shrews, which was accompanied by significant increases in c-Fos expression and ERK1/2 phosphorylation in the shrew brainstem dorsal vagal complex, indicating activation of brainstem emetic nuclei in m-3M3FBS-evoked emesis. The m-3M3FBS-evoked vomiting was reduced by pretreatment with diverse antiemetics including the antagonists/inhibitors of: PLC (U73122), L-type Ca channel (nifedipine), IPR (2-APB), RyR receptor (dantrolene), ERK1/2 (U0126), PKC (GF109203X), the serotoninergic type 3 receptor (palonosetron), and neurokinin 1 receptor (netupitant). In addition, the PLC inhibitor U73122 displayed broad-spectrum antiemetic effects against diverse emetogens, including the selective agonists of serotonin type 3 (2-Methyl-5-HT)-, neurokinin 1 receptor (GR73632), dopamine D (quinpirole)-, and muscarinic M (McN-A-343) receptors, the L-type Ca channel (FPL64176), and the sarco/endoplasmic reticulum Ca-ATPase inhibitor thapsigargin. In sum, PLC activation contributes to emesis, whereas PLC inhibition suppresses vomiting evoked by diverse emetogens.
Gq和Gβγ蛋白依赖性磷脂酶C(PLC)的激活广泛参与G蛋白偶联受体(GPCR)介导的信号通路,这些信号通路与多种生理和病理事件有关。刺激几种GPCR,如P物质神经激肽1受体、多巴胺D受体、组胺H受体和μ-阿片受体,可导致呕吐。本研究的目的是通过评估PLC激活剂(m-3M3FBS)的催吐潜力和PLC抑制剂(U73122)在最小的鼩鼱呕吐模型中的止吐效果,来研究PLC在呕吐中的作用。我们发现,50mg/kg(腹腔注射)剂量的m-3M3FBS可在约90%的受试最小鼩鼱中诱发呕吐,同时伴随着鼩鼱脑干背迷走复合体中c-Fos表达和ERK1/2磷酸化的显著增加,表明m-3M3FBS诱发呕吐时脑干催吐核被激活。m-3M3FBS诱发的呕吐可通过用多种止吐药预处理而减少,这些止吐药包括以下拮抗剂/抑制剂:PLC(U73122)、L型钙通道(硝苯地平)、肌醇1,4,5-三磷酸受体(2-APB)、兰尼碱受体(丹曲林)、ERK1/2(U0126)、蛋白激酶C(GF109203X)、5-羟色胺能3型受体(帕洛诺司琼)和神经激肽1受体(奈妥吡坦)。此外,PLC抑制剂U73122对多种催吐剂显示出广谱止吐作用,这些催吐剂包括5-羟色胺3型(2-甲基-5-羟色胺)、神经激肽受体1(GR73632)、多巴胺D受体(喹吡罗)、毒蕈碱M受体(McN-A-343)的选择性激动剂、L型钙通道(FPL64176)以及肌浆网/内质网钙-ATP酶抑制剂毒胡萝卜素。总之,PLC激活促进呕吐,而PLC抑制可抑制多种催吐剂诱发的呕吐。